Vest Financial LLC Has $1.16 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Vest Financial LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 73.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,392 shares of the biopharmaceutical company's stock after buying an additional 4,403 shares during the period. Vest Financial LLC's holdings in Gilead Sciences were worth $1,164,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Newbridge Financial Services Group Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $33,000. Annis Gardner Whiting Capital Advisors LLC raised its holdings in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares during the period. Morton Brown Family Wealth LLC acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $35,000. Whipplewood Advisors LLC bought a new position in Gilead Sciences in the fourth quarter valued at approximately $35,000. Finally, Synergy Investment Management LLC acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $40,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analysts Set New Price Targets

GILD has been the topic of several research reports. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. Royal Bank of Canada boosted their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. Morgan Stanley increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, Wells Fargo & Company upped their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.54 during trading on Monday, reaching $113.00. 6,149,820 shares of the stock were exchanged, compared to its average volume of 7,745,018. Gilead Sciences, Inc. has a 12 month low of $62.69 and a 12 month high of $119.96. The stock has a 50-day moving average price of $105.39 and a 200-day moving average price of $101.64. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market cap of $140.56 billion, a PE ratio of 305.41, a PEG ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm's quarterly revenue was down .3% on a year-over-year basis. During the same period in the previous year, the company posted ($1.32) EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.80%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,000 shares of company stock valued at $4,630,310 in the last quarter. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.